The 5 most recent market catalysts affecting $ERNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Ernexa Therapeutics has released highly encouraging safety data for ERNA-101, its lead synthetic iMSC therapy. The successful completion of repeat-dose toxicology, tumorigenicity, …
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics (ERNA) reported that an independent preclinical study confirmed the efficacy of its ERNA-101 cell therapy in combination with PD-1 checkpoint inhibition, showin…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 85
Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.
The positive preclinical data for ERNA-101, especially in combination with PD-1 checkpoint inhibition, is a strong corporate catalyst for Ernexa Therapeutics. This validation signi…
Jul 15, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
This filing highlights pre-market trading activity for 12 health care stocks, showing considerable volatility with some experiencing gains of over 88% and others declines of over 3…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (ERNA) released positive preclinical data for its lead cell therapy candidate, ERNA-101, demonstrating complete tumor clearance and durable long-term survival i…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.